Gielerak Grzegorz, Makowski Karol, Dłuzniewska Ewa, Stec Alicja, Cholewa Marian
Department of Internal Diseases and Cardiology, Military Medical Institute, Warsaw, Poland.
Kardiol Pol. 2003 Aug;59(8):93-104; commentary 103-4.
Although beta blockers are frequently used for the prevention of recurrences of vaso-vagal syncope, the prediction of the long-term efficacy of this treatment is difficult.
To assess whether the result of tilt testing with an intravenous beta blocker can predict the long-term efficacy of beta blockade.
The study group consisted of 62 patients (29 females, mean age 32.8+/-12.3 years and 33 males, mean age 35.9+/-18.2 years) with at least two syncopal episodes during the six months preceding positive tilt testing. After baseline tilt test, propranolol in a dose of 0.1 mg/kg body weight was administered intravenously and the tilt test was repeated. Beta blockade was defined effective if the second tilt test was negative (complete efficacy) or the time to syncope during tilt testing was increased compared with the baseline tilting (partial efficacy). All patients received chronic propranolol treatment and were followed for one year or till the recurrence of syncope.
Intravenous propranolol prevented (n=33) or delayed (n=18) syncope during tilt testing in 51 (82%) patients whereas it was ineffective in the remaining 11 (18%) patients. During 8.6+/-6.7 (range 1-14) months of follow-up, 20 (32%) patients had syncope recurrence; 13 (25%) from the group with effective intravenous propranolol versus 7 (64%) patients in whom intravenous propranolol did not prevent syncope during tilt testing (p<0.015). Analysis of survival without a recurrence of syncope revealed a significant relationship between the results of tilt testing with intravenous propranolol and the efficacy of long-term beta-blocker therapy (p<0.003). There were no significant differences between the predictive value of tilt testing with propranolol between patients with complete or partial propranolol efficacy (NS) whereas significant differences between each of these two groups and patients with ineffective intravenous propranolol were noted (p<0.04 and p<0.002, respectively).
Propranolol administered intravenously prevents syncope during tilt testing in a significant proportion of patients. Both complete or partial efficacy of intravenous propranolol predict long-term efficacy of chronic beta blocker therapy in patients with vaso-vagal syncope.
尽管β受体阻滞剂常用于预防血管迷走性晕厥复发,但预测该治疗的长期疗效存在困难。
评估静脉注射β受体阻滞剂后的倾斜试验结果能否预测β受体阻滞剂的长期疗效。
研究组由62例患者组成(29例女性,平均年龄32.8±12.3岁;33例男性,平均年龄35.9±18.2岁),这些患者在倾斜试验阳性前6个月内至少有两次晕厥发作。在基线倾斜试验后,静脉注射剂量为0.1mg/kg体重的普萘洛尔,然后重复倾斜试验。如果第二次倾斜试验为阴性(完全有效)或倾斜试验期间晕厥时间较基线倾斜试验延长(部分有效),则定义β受体阻滞剂有效。所有患者均接受普萘洛尔长期治疗,并随访1年或直至晕厥复发。
静脉注射普萘洛尔可预防(n=33)或延迟(n=18)51例(82%)患者在倾斜试验期间的晕厥,而其余11例(18%)患者无效。在8.6±6.7(范围1 - 14)个月的随访期间,20例(32%)患者晕厥复发;静脉注射普萘洛尔有效的组中有13例(25%)复发,而静脉注射普萘洛尔未能预防倾斜试验期间晕厥的患者中有7例(64%)复发(p<0.015)。对无晕厥复发的生存情况分析显示,静脉注射普萘洛尔的倾斜试验结果与长期β受体阻滞剂治疗的疗效之间存在显著相关性(p<0.003)。普萘洛尔完全有效或部分有效的患者之间,倾斜试验的预测价值无显著差异(无统计学意义),但这两组与静脉注射普萘洛尔无效的患者之间均存在显著差异(分别为p<0.04和p<0.002)。
静脉注射普萘洛尔可使相当一部分患者在倾斜试验期间避免晕厥。静脉注射普萘洛尔的完全或部分有效性均可预测血管迷走性晕厥患者慢性β受体阻滞剂治疗的长期疗效。